Causes of death
. | Treated patients, n (%) . | |
---|---|---|
Dasatinib, N = 258 . | Imatinib, N = 258 . | |
Total deaths | 16 (6) | 14 (5) |
Death on study treatment or within 30 days of last dose | 7 (3) | 4 (2) |
Death > 30 days after discontinuing study treatment | 9 (3) | 10 (3) |
Causes of death | ||
CML progression | 8 (3) | 10 (4) |
Cardiovascular disease | 2 (1) | 1 (< 1) |
Infection | 5 (2) | 1 (< 1) |
Bleeding | 0 | 1 (< 1) |
Other neoplasm | 1 (< 1) | 0 |
Clinical deterioration* | 0 | 1 (< 1) |
. | Treated patients, n (%) . | |
---|---|---|
Dasatinib, N = 258 . | Imatinib, N = 258 . | |
Total deaths | 16 (6) | 14 (5) |
Death on study treatment or within 30 days of last dose | 7 (3) | 4 (2) |
Death > 30 days after discontinuing study treatment | 9 (3) | 10 (3) |
Causes of death | ||
CML progression | 8 (3) | 10 (4) |
Cardiovascular disease | 2 (1) | 1 (< 1) |
Infection | 5 (2) | 1 (< 1) |
Bleeding | 0 | 1 (< 1) |
Other neoplasm | 1 (< 1) | 0 |
Clinical deterioration* | 0 | 1 (< 1) |
The patient who died after clinical deterioration while receiving imatinib therapy had progressive severe grade 4 peripheral edema despite diuretics, with acute renal failure and rapid decline in performance status ultimately leading to cardiorespiratory arrest. The leading cause of death was unknown.